Carey Crill
Psychiatric/Mental Health · Boise, IDNPI 1457530693
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Axsome Therapeutics, Inc. accounts for 62.9% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $10,308 and has fallen 95.2% since, to $496 in 2025. Among psychiatric/mental health clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $60.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$12K
- Johnson & Johnson$2K
- Neuronetics, Inc.$1K
- AbbVie$975
- Supernus Pharmaceuticals, Inc.$600
- Otsuka America Pharmaceutical, Inc.$407
- plus $2K from 18 others
What the payments were for
- Consulting fees$9,58850%
- Speaking & faculty fees$9755%
- Travel & lodging$2,99116%
- Food & beverage$5,60029%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 20 | $12,061 |
| Johnson & Johnson | 34 | $1,578 |
| Neuronetics, Inc. | 2 | $1,372 |
| AbbVie | 75 | $975 |
| Supernus Pharmaceuticals, Inc. | 34 | $600 |
| Otsuka America Pharmaceutical, Inc. | 22 | $407 |
| Alkermes, Inc. | 17 | $270 |
| Teva Pharmaceuticals USA, Inc. | 12 | $243 |
| Lundbeck LLC | 16 | $237 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $230 |
| Neurocrine Biosciences, Inc. | 8 | $220 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $174 |
| Corium, LLC | 13 | $148 |
| Eisai Inc. | 9 | $119 |
| Vanda Pharmaceuticals Inc. | 7 | $115 |
| Tris Pharma Inc | 4 | $98 |
| Merck | 6 | $95 |
| Sunovion Pharmaceuticals Inc. | 4 | $80 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Indivior Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$11,895
- NEUROSTAR TMS THERAPY$1,372
- SPRAVATO$1,143
- QELBREE$103
How this compares
$19,168 in reported general payments places this provider in the 95th percentile of 221 psychiatric/mental health providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 49 | $90,405 |
| AristadaAripiprazole Lauroxil | 17 | $51,894 |
| Invega SustennaPaliperidone Palmitate | 13 | $44,367 |
| VraylarCariprazine Hcl | 15 | $21,419 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $18,446 |
| BelsomraSuvorexant | 34 | $15,950 |
| TrintellixVortioxetine Hydrobromide | 23 | $11,796 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 19 | $9,397 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $9,085 |
| Olanzapine | 67 | $7,421 |
| Jornay PmMethylphenidate Hcl | 12 | $5,676 |
| Paliperidone ErPaliperidone | 22 | $4,353 |
| Aripiprazole | 42 | $2,641 |
| Asenapine Maleate | 16 | $2,553 |
| Oxcarbazepine | 14 | $1,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna | $1,578 | $134,77262 claims |
| Alkermes, Inc.Aristada, Lybalvi | $270 | $70,34029 claims |
| AbbVieVraylar | $975 | $21,41915 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $174 | $20,88243 claims |
| MerckBelsomra | $95 | $15,95034 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $35 | $5,67612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 221 psychiatric/mental health providers in Idaho.
Other psychiatric/mental health in Boise
- Misti NewsonBoise$56K
- Julie SchraderBoise$9K
- Susan DayBoise$9K
- Grace MensahBoise$6K
- Katie HarpBoise$6K
- Eliza SalazarBoise$5K
- Brigitta PantherBoise$5K
- Dawn LoceyBoise$3K
- Lisa BrynerBoise$3K
- Jenny PinsonBoise$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.